What happened
- On 17 Nov 2026 the FDA granted accelerated approval to neladalkib (Nelkarmi, Nuvalent) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer.
- It is for people previously treated with alectinib, or with two or more ALK inhibitors plus platinum chemotherapy.
What we don't know yet
- Accelerated approval means confirmatory trials must still show clinical benefit.
- The FDA notice we read gives the indication; trial numbers are in the label, not summarised here yet.
Primary sources
- FDA oncology approval notifications (17 Nov 2026 entry)Regulator decision
Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.